valproic acid has been researched along with Mesothelioma in 6 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Mesothelioma: A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The goal of this study was to evaluate the anticancer effect of a histone deacetylase inhibitor, valproate, on mesothelioma cells in combination with pemetrexed and cisplatin, the usual first-line regimen of chemotherapy for this tumor." | 7.75 | Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. ( Burny, A; Delvenne, P; Grigoriu, B; Hubert, P; Mascaux, C; Scherpereel, A; Vandermeers, F; Willems, L, 2009) |
| " The goal of this study was to evaluate the anticancer effect of a histone deacetylase inhibitor, valproate, on mesothelioma cells in combination with pemetrexed and cisplatin, the usual first-line regimen of chemotherapy for this tumor." | 3.75 | Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. ( Burny, A; Delvenne, P; Grigoriu, B; Hubert, P; Mascaux, C; Scherpereel, A; Vandermeers, F; Willems, L, 2009) |
| "Malignant pleural mesothelioma is known to be widely resistant to therapy and new treatment strategies are needed." | 1.37 | Lovastatin and valproic acid additively attenuate cell invasion in ACC-MESO-1 cells. ( Asakura, K; Fukutomi, T; Izumi, Y; Kawai, K; Nomori, H; Serizawa, A; Suematsu, M; Wakui, M; Yamauchi, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bensaid, D | 1 |
| Blondy, T | 1 |
| Deshayes, S | 1 |
| Dehame, V | 1 |
| Bertrand, P | 1 |
| Grégoire, M | 3 |
| Errami, M | 1 |
| Blanquart, C | 3 |
| Vandermeers, F | 1 |
| Hubert, P | 1 |
| Delvenne, P | 1 |
| Mascaux, C | 1 |
| Grigoriu, B | 1 |
| Burny, A | 1 |
| Scherpereel, A | 2 |
| Willems, L | 2 |
| Berghmans, T | 1 |
| Lafitte, JJ | 1 |
| Colinet, B | 1 |
| Richez, M | 1 |
| Bonduelle, Y | 1 |
| Meert, AP | 1 |
| Dhalluin, X | 1 |
| Leclercq, N | 1 |
| Paesmans, M | 1 |
| Sculier, JP | 1 |
| Leclercq, S | 1 |
| Gueugnon, F | 2 |
| Boutin, B | 1 |
| Guillot, F | 1 |
| Rogel, A | 1 |
| Padieu, M | 1 |
| Pouliquen, D | 1 |
| Fonteneau, JF | 2 |
| Yamauchi, Y | 1 |
| Izumi, Y | 1 |
| Asakura, K | 1 |
| Fukutomi, T | 1 |
| Serizawa, A | 1 |
| Kawai, K | 1 |
| Wakui, M | 1 |
| Suematsu, M | 1 |
| Nomori, H | 1 |
| Roulois, D | 1 |
| Panterne, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study Assessing the Activity of Valproate Acid Plus Doxorubicin in Refractory or Recurrent Malignant Mesothelioma[NCT00634205] | Phase 2 | 45 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for valproic acid and Mesothelioma
| Article | Year |
|---|---|
Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Diseas | 2011 |
5 other studies available for valproic acid and Mesothelioma
| Article | Year |
|---|---|
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Topics: B7-H1 Antigen; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Meth | 2018 |
Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BH3 Inter | 2009 |
A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, | 2011 |
Lovastatin and valproic acid additively attenuate cell invasion in ACC-MESO-1 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; | 2011 |
Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.
Topics: Antigens, Neoplasm; Azacitidine; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Decitabine; Down-Regu | 2012 |